The First Pre-clinical Mouse Study Using Ischemia-Tolerant
Mesenchymal Stem Cells (itMSCs) Shows Over 30-Percent Decrease in
Amyloid Beta (Abeta) Plaques
EPALINGES, Switzerland--(BUSINESS WIRE)--
Stemedica International S.A., a Stemedica Cell Technologies Inc.
subsidiary developing stem cell therapies for Alzheimer’s disease and
dementia, revealed the first results of an intravenous administration of
allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in
a pre-clinical animal model of Alzheimer’s disease. The results
demonstrated a greater than 30-percent decrease in amyloid beta (Abeta)
plaques in the brain of transgenic animals treated with Stemedica itMSCs
compared to the control group that were treated with lactated Ringer’s
“Pre-clinical results show Stemedica International’s treatment reduces
the amount of plaque as much as the best drug candidates to manage Abeta
amyloidosis,” says Stemedica International’s Chief Scientist Tristan
Bolmont, Ph.D. “Most importantly, our itMSC treatment did not result in
side effects, such as cerebral amyloid angiopathy and micro-hemorrhages.”
These promising results were achieved during a two-year, intensive,
pre-clinical research project supported by a grant from the Swiss
Commission for Technology and Innovation (CTI). The research was
conducted at the Laboratoire d’Optique Biomedicale and headed by
Professor Theo Lasser at École Polytechnique FÉdÉrale de Lausanne (EPFL)
The results were presented at the Alzheimer’s Association International
Conference in Copenhagen, Denmark, on July 14, 2014. In addition, Dr.
Bolmont will share the findings during his talk at the Stem Cells
Regenerative Medicine Congress 2014 in Boston, Massachusetts, on Sept.
15 at 2:30 p.m. ET.
“The combination of safety and efficacy of Stemedica’s itMSCs clears the
pathway for Stemedica International to file an IND application with the
FDA for clinical trials,” says Stemedica International’s General Manager
Alexei Lukashev, Ph.D. “We hope our stem cell treatment can halt or slow
down the progression of Alzheimer's disease and, maybe, have some
reverse effect on the damage caused by Alzheimer’s disease and other
forms of dementia, which the Alzheimer’s Disease Institute estimates
afflicts more than 44 million people worldwide today.”
Only Stemedica International’s therapies feature itMSCs that are
exclusively licensed from the parent company Stemedica Cell
Technologies, Inc. Unlike other MSCs – which are grown under normoxic
conditions – Stemedica’s bone-marrow-derived, allogeneic itMSCs are
unique because they are grown under hypoxic conditions. In vitro
experiments demonstrate cells that are exposed to hypoxic conditions
show greater homing and engraftment than cells grown under normoxic
conditions. Compared to other MSCs, itMSCs secrete higher levels of
growth factors and other important proteins associated with
neoangiogenesis and healing.
About Stemedica International S.A.
Founded in Epalinges, Switzerland, in 2008, Stemedica International S.A.
is a global biotechnology company that develops therapeutic applications
for the treatment and prevention of Alzheimer’s disease and vascular
dementia. The company is a subsidiary of Stemedica Cell Technologies,
Inc., a global biotechnology company that manufactures adult allogeneic
stem cells. Stemedica International has an exclusive license to
manufacture and distribute the parent company’s allogeneic,
ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant
neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s
disease and vascular dementia indications. The company also has
Swissmedic licenses to import, export and distribute Stemedica Cell
Technologies’ cell lines worldwide for human use in approved clinical
trials. Manufactured in compliance with cGMP standards, the stem cell
lines have a unique, proprietary technology based on the expansion of
cells in constant hypoxia, which provides critical benefits in terms of
safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
The Townsend Team
Stemedica International S.A.
David Cheatham, MBA,
+41 (0)21 651 9050
Source: Stemedica International S.A.